Janus kinase inhibitors in dermatology: Part II. A comprehensive review

J Am Acad Dermatol. 2022 Feb;86(2):414-422. doi: 10.1016/j.jaad.2021.06.873. Epub 2021 Jul 3.


The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is implicated in the pathogenesis of a number of inflammatory dermatoses. Clinical trials and other studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here we review JAK inhibitors currently under investigation for the treatment of alopecia areata, vitiligo, sarcoidosis, necrobiosis lipoidica, granuloma annulare, and systemic lupus erythematosus with a special emphasis on safety and the implications of JAK inhibitors during the novel coronavirus 2019 pandemic.

Keywords: COVID-19; JAK inhibitor; JAK-STAT pathway; Janus kinase inhibitor; Janus kinase-signal transducer and activator of transcription pathway; coronavirus; dermatology; immunodermatology; immunology; review.

Publication types

  • Review

MeSH terms

  • COVID-19
  • Dermatology* / trends
  • Humans
  • Janus Kinase Inhibitors* / therapeutic use
  • Skin Diseases / drug therapy*


  • Janus Kinase Inhibitors